Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Selective serotonin reuptake inhibitors for late-life depression - A comparative review
Autore:
Solai, LKK; Mulsant, BH; Pollock, BG;
Indirizzi:
Univ Pittsburgh, Sch Med, Pittsburgh, PA USA Univ Pittsburgh Pittsburgh PA USA ittsburgh, Sch Med, Pittsburgh, PA USA VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PAUSA VA Pittsburgh Healthcare Syst Pittsburgh PA USA Clin, Pittsburgh, PAUSA Univ Pittsburgh Med Ctr, Geriatr Psychopharmacol Program, Western PsychiatInst & Clin, Pittsburgh, PA USA Univ Pittsburgh Med Ctr Pittsburgh PA USAnst & Clin, Pittsburgh, PA USA
Titolo Testata:
DRUGS & AGING
fascicolo: 5, volume: 18, anno: 2001,
pagine: 355 - 368
SICI:
1170-229X(2001)18:5<355:SSRIFL>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
NURSING-HOME RESIDENTS; HUMAN LIVER-MICROSOMES; COMPLICATING ALZHEIMERS-DISEASE; TRIAL COMPARING SERTRALINE; MULTICENTER DOUBLE-BLIND; MAJOR DEPRESSION; IN-VITRO; CLINICAL-TRIAL; GERIATRIC-PATIENTS; POTENT INHIBITOR;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Solai, LKK UPMC, Beaver Valley Mental Hlth Serv, 176 Virginia Ave, Rochester, PA 15074 USA UPMC 176 Virginia Ave Rochester PA USA 15074 ster, PA 15074 USA
Citazione:
L.K.K. Solai et al., "Selective serotonin reuptake inhibitors for late-life depression - A comparative review", DRUG AGING, 18(5), 2001, pp. 355-368

Abstract

Late-life depression is a serious health problem that is challenging to manage but generally responds well to pharmacotherapy. Selective serotonin (5-hydroxy-tryptamine; 5-HT) reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants. are usually used as first-line agents for elderly patients with depression. Like most drugs, SSRIs have not been widely tested in clinical trials that approximate 'real-life' geriatric situations. However. studies completed to dare provide valuable information about the efficacy, safety and tolerability of this class of antidepressants among older patients with depression, including those with depression secondary to stroke or dementia and those with other comorbid physical disorders. Although one SSRI may be more efficacious or better tolerated by elderly patients than another. existing data do not support such claims. However. other distinguishing features may influence the choice of agent. For example,fluoxetine, fluvoxamine and paroxetine are more likely to be involved in significant drug-drug interactions than are citalopram or sertraline. In contrast to the other SSRIs, fluoxetine has a half-life well in excess of 1 day, which can be an advantage when weaning the patient off therapy in that it may reduce the incidence of discontinuation symptoms, but a significant disadvantage if the patient cannot tolerate the drug or experiences an adverse drug-drug interaction.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/02/20 alle ore 15:00:23